mRNA-1647 cytomegalovirus vaccine clinical trials
Also written mRNA-1647.
How each study uses mRNA-1647 cytomegalovirus vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- mRNA-1647
- 9
Studies by the year they started
9 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
2019-nCoV Vaccine mRNA-1273 (1) · mRNA-1010 influenza vaccine (1) · mRNA-1345 respiratory syncytial virus vaccine (1) · MRNA-1443 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test mRNA-1647 cytomegalovirus vaccine.
Studies
Open first, then newest update. How each study uses mRNA-1647 cytomegalovirus vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Active, not recruitingPhase 2ModernaTX, Inc.NCT05683457Written as mRNA-1647How we know
- A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgeCompletedPhase 1/2ModernaTX, Inc.NCT05575492Written as mRNA-1647How we know
- Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy AdultsCompletedPhase 2ModernaTX, Inc.NCT04232280Written as mRNA-1647How we know
- A Study of Modified mRNA Vaccines in Healthy AdultsCompletedPhase 1ModernaTX, Inc.NCT05397223Written as mRNA-1647How we know
- A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineCompletedPhase 2ModernaTX, Inc.NCT04975893Written as mRNA-1647How we know
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeTerminatedPhase 3ModernaTX, Inc.NCT05085366Written as mRNA-1647How we know
- A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and RecipientsWithdrawnPhase 2ModernaTX, Inc.NCT06133010Written as mRNA-1647How we know
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647CompletedPhase 1ModernaTX, Inc.NCT05105048Written as mRNA-1647How we know
- Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy AdultsCompletedPhase 1ModernaTX, Inc.NCT03382405Written as mRNA-1647How we know
Codes
What other systems call mRNA-1647 cytomegalovirus vaccine · ClinicalTrials.gg INT001889
- MeSH (NLM) C000722750mRNA-1647 cytomegalovirus vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722750 | mRNA-1647 cytomegalovirus vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.